SCHEMBL20595848

SCHEMBL20595848

COc1ccc(-c2ccc(NC(C)=O)c3nc(Cc4nc5ccc(Cl)cc5[nH]4)cn23)c(Cl)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ MAPT P10636 2/20 0.39
▸ GAA P10253 1/20 0.39
▸ ALDH1A1 P00352 3/20 0.39
▸ TDP1 Q9NUW8 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ AMY1A P0DUB6 1/20 0.39
▸ PRMT5 O14744 4/20 0.39
▸ WDR77 Q9BQA1 4/20 0.39
▸ FPR2 P25090 1/20 0.39
▸ GRIN1 Q05586 2/20 0.38
▸ GRIN2B Q13224 2/20 0.38
▸ EGFR P00533 1/20 0.37
▸ ERBB2 P04626 1/20 0.37
▸ KDR P35968 1/20 0.36
▸ MARS2 Q96GW9 4/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23419554 0.94 MARS2 (0.38) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL20595970 0.94 MEN1 (0.39) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL20595586 0.91 ABL1 (0.41) MEN1KMT2AMAPTGAAAMY1A
SCHEMBL30145089 0.91 ABL1 (0.41) MEN1KMT2AMAPTGAAAMY1A
SCHEMBL23419287 0.88 MARS2 (0.40) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL20595877 0.86 MARS2 (0.52) MAPTALDH1A1KDM4EHSD17B10PRMT5
SCHEMBL23419396 0.85 NTRK1 (0.37) MAPTALDH1A1KDM4ETP53PRMT5
SCHEMBL20595745 0.85 MARS2 (0.54) MAPTALDH1A1KDM4EPRMT5WDR77
SCHEMBL20595816 0.85 MARS2 (0.43) MAPTALDH1A1KDM4EHSD17B10PRMT5
SCHEMBL30145234 0.85 MARS2 (0.54) MAPTALDH1A1KDM4EPRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON 2021-05-27 — — US claimed
WO-2018237349-A1 INHIBITORS OF TYPED 1 METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON (US) 2018-12-27 — — WO claimed
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them UNIVERSITY OF WASHINGTON (US) 2023-02-21 — — US disclosed
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON 2021-05-27 — — US disclosed
WO-2018237349-A1 INHIBITORS OF TYPED 1 METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON (US) 2018-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them AARS1, EMG1, GARS1 MEN1 1598/4885KMT2A 1475/4885MAPT 3686/4885
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM AARS1, GARS1, MTR MEN1 2393/4885KMT2A 1280/4885MAPT 3436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback